Ioxaglate versus IoDixanol for the prevention of contrast-induced nephropathy: the IDPC trial
J. invasive cardiol; 35 (6), 2023
BACKGROUND. Despite the potential benefits of percutaneous procedures for the assessment and treatment of coronary artery disease, these interventions require the use of iodine contrast, which might lead to contrast-induced nephropathy (CIN) and increased risk of dialysis and major adverse cardiac events...